Whitehawk Therapeutics (WHWK) EBT (2010 - 2026)

Whitehawk Therapeutics (WHWK) has 17 years of EBT data on file, last reported at -$22.2 million in Q1 2026.

• EBT for Q1 2026 came in at -$22.2 million, down 130.4% year-over-year; the trailing twelve-month figure through Mar 2026 was -$5.9 million (down 121.22% YoY), and the FY2025 annual result was -$20.6 million, up 67.66% from the prior year.
• EBT declined to -$22.2 million in Q1 2026 per WHWK's latest filing, from $86.8 million in the prior quarter.
• Over five years, EBT peaked at $86.8 million in Q4 2025 and troughed at -$52.8 million in Q2 2025.
• A 5-year average of -$7.2 million and a median of -$16.3 million in 2023 frame the typical range for EBT.
• The sharpest annual moves came in 2022 and 2025: EBT plunged 1090.35% in 2022, then soared 575.01% in 2025.
• A 5-year view of EBT shows it stood at -$13.9 million in 2022, then retreated by 16.86% to -$16.3 million in 2023, then retreated by 12.32% to -$18.3 million in 2024, then soared by 575.01% to $86.8 million in 2025, then sank by 125.57% to -$22.2 million in 2026.
• Business Quant data shows WHWK's EBT at -$22.2 million in Q1 2026, $86.8 million in Q4 2025, and -$17.7 million in Q3 2025.